Literature DB >> 9863490

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

I Madeira1, B Terris, M Voss, A Denys, A Sauvanet, J F Flejou, V Vilgrain, J Belghiti, P Bernades, P Ruszniewski.   

Abstract

BACKGROUND: The development of endocrine tumours of the duodenopancreatic area (ETDP) is thought to be slow, but their natural history is not well known. The aim of this study was to determine the factors that influence survival of patients with ETDP. PATIENTS/
METHODS: Eighty two patients with ETDP (44 non-functioning tumours, 23 gastrinomas, seven calcitonin-secreting tumours, four glucagonomas, three insulinomas, one somatostatinoma) followed from October 1991 to June 1997 were included in the study. The following factors were investigated: primary tumour size, hormonal clinical syndrome, liver metastases, lymph node metastases, extranodular/extrahepatic metastases, progression of liver metastases, local invasion, complete resection of the primary tumour, and degree of tumoral differentiation. The prognostic significance of these factors was investigated by uni- and multi-variate analysis.
RESULTS: Twenty eight patients (34%) died within a median of 17 months (range 1-110) from diagnosis. Liver metastases (p = 0.001), lymph node metastases (p = 0.001), progression of liver metastases (p < 0.00001), lack of complete resection of the primary tumour (p = 0.001), extranodular/extrahepatic metastases (p = 0.001), local invasion (p = 0.001), primary tumour size > or = 3 cm (p = 0.001), non-functioning tumours (p = 0.02), and poor tumoral differentiation (p = 0.006) were associated with an unfavourable outcome by univariate analysis. Multivariate analysis identified only liver metastases (risk ratio (RR) = 8.3; p < 0.0001), poor tumoral cell differentiation (RR = 8.1; p = 0.0001), and lack of complete resection of the primary tumour (RR = 4.8; p = 0.0007) as independent risk factors. Five year survival rates were 40 and 100% in patients with and without liver metastases, 85 and 42% in patients with and without complete resection of primary tumour, and 17 and 71% in patients with poor and good tumour cell differentiation respectively.
CONCLUSION: Liver metastases are a major prognostic factor in patients with ETDP. Progression of liver metastases is also an important factor which must be taken into account when deciding on the therapeutic approach. The only other independent prognostic factors are tumoral cell differentiation and complete resection of the primary tumour.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863490      PMCID: PMC1727238          DOI: 10.1136/gut.43.3.422

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Current approach to the management of tumoral process in patients with gastrinoma.

Authors:  M Mignon; P Ruszniewski; S Haffar; D Rigaud; E Rene; S Bonfils
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

2.  Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients.

Authors:  B Eriksson; K Oberg; B Skogseid
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

Review 3.  Diagnosis and treatment of Zollinger-Ellison syndrome.

Authors:  M Mignon; S Bonfils
Journal:  Baillieres Clin Gastroenterol       Date:  1988-07

4.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Authors:  C G Moertel; L K Kvols; M J O'Connell; J Rubin
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

5.  Cytoreductive hepatic surgery for neuroendocrine tumors.

Authors:  G P McEntee; D M Nagorney; L K Kvols; C G Moertel; C S Grant
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

6.  Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.

Authors:  W D Travis; R I Linnoila; M G Tsokos; C L Hitchcock; G B Cutler; L Nieman; G Chrousos; H Pass; J Doppman
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

7.  The role of morphometry in predicting prognosis in pancreatic islet cell tumors.

Authors:  B D Kenny; J M Sloan; P W Hamilton; P C Watt; C F Johnston; K D Buchanan
Journal:  Cancer       Date:  1989-07-15       Impact factor: 6.860

8.  Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin.

Authors:  G Viale; C Doglioni; M Gambacorta; G Zamboni; G Coggi; C Bordi
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

9.  Benign and malignant gastrinoma.

Authors:  B E Stabile; E Passaro
Journal:  Am J Surg       Date:  1985-01       Impact factor: 2.565

10.  Gastrinoma: factors influencing prognosis.

Authors:  R M Zollinger
Journal:  Surgery       Date:  1985-01       Impact factor: 3.982

View more
  50 in total

Review 1.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

2.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

3.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 4.  Pancreatic neuroendocrine tumors: overview of recent advances and diagnosis.

Authors:  Robert T Jensen
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

5.  Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE.

Authors:  Kimberly A Varker; Edward W Martin; Dori Klemanski; Bryan Palmer; Manisha H Shah; Mark Bloomston
Journal:  J Gastrointest Surg       Date:  2007-09-25       Impact factor: 3.452

Review 6.  Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Masayuki Imamura; Izumi Komoto; Shuichi Ota
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

Review 7.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 8.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

9.  High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour.

Authors:  Yitao Gong; Zhiyao Fan; Pin Zhang; Yunzhen Qian; Qiuyi Huang; Shengming Deng; Guopei Luo; He Cheng; Kaizhou Jin; Quanxing Ni; Xianjun Yu; Chen Liu
Journal:  Endocrine       Date:  2020-08-29       Impact factor: 3.633

Review 10.  [Indications and operative procedures for neuroendocrine liver metastases].

Authors:  T J Musholt; H Lang
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.